Nifty
:
25727.55
Sensex
:
83739.13
639.15 (2.55%)
2072.67 (2.54%)
Nifty
Sensex
:
:
25727.55
83739.13
639.15 (2.55%)
2072.67 (2.54%)

Ajanta Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
74/99

BSE: 532331 | NSE: AJANTPHARM

NSE BSE
2880.10
03-Feb-2026
  • Open
  • High
  • Low
  • Previous Close
  •  2856.6
  •  2889
  •  2785.1
  •  2785.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  119919
  •  342430534.4
  •  3020.8
  •  2327.3

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 35,972.09
  • 35.46
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 36,082.71
  • 0.97%
  • 7.84

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 66.25%
  • 0.17%
  • 6.44%
  • FII
  • DII
  • Others
  • 7.97%
  • 18.15%
  • 1.02%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.36
  • 9.97
  • 7.49

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.93
  • 4.75
  • 9.97

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.28
  • 7.08
  • 16.11

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.55
  • 32.24
  • 35.71

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.88
  • 6.69
  • 7.72

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.57
  • 20.63
  • 23.64

Earnings Forecasts:

(Updated: 31-01-2026)
Description
2024
2025
2026
2027
Adj EPS
73.56
82.07
95.73
109.45
P/E Ratio
39.15
35.09
30.09
26.31
Revenue
4587.51
5261.96
5904.17
6600.69
EBITDA
1259.5
1414.45
1664.56
1904.14
Net Income
920.39
1030.26
1200.49
1372.71
ROA
19.07
19.58
19.81
19.56
P/B Ratio
9.55
8.16
7.03
5.80
ROE
25.02
24.73
24.61
24.08
FCFF
866.08
547.1
1069.67
1017.33
FCFF Yield
2.59
1.64
3.2
3.05
Net Debt
-567.53
-519
-586.93
298.9
BVPS
301.59
352.87
409.7
496.99

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
1,374.84
1,146.13
19.95%
1,353.73
1,186.64
14.08%
1,302.65
1,144.92
13.78%
1,170.41
1,054.08
11.04%
Expenses
992.60
825.30
20.27%
1,025.90
875.47
17.18%
951.30
814.57
16.79%
873.26
775.76
12.57%
EBITDA
382.24
320.83
19.14%
327.83
311.17
5.35%
351.35
330.35
6.36%
297.15
278.32
6.77%
EBIDTM
27.80%
27.99%
24.22%
26.22%
26.97%
28.85%
25.39%
26.40%
Other Income
24.97
30.44
-17.97%
59.34
19.48
204.62%
26.33
26.47
-0.53%
18.11
35.50
-48.99%
Interest
5.10
7.91
-35.52%
3.39
6.02
-43.69%
5.26
0.73
620.55%
6.07
1.53
296.73%
Depreciation
43.51
35.97
20.96%
42.97
34.39
24.95%
41.29
33.97
21.55%
39.78
34.25
16.15%
PBT
358.60
307.39
16.66%
340.81
290.24
17.42%
331.13
322.12
2.80%
269.41
278.04
-3.10%
Tax
84.83
74.51
13.85%
80.62
73.76
9.30%
75.79
76.35
-0.73%
44.15
75.32
-41.38%
PAT
273.77
232.88
17.56%
260.19
216.48
20.19%
255.34
245.77
3.89%
225.26
202.72
11.12%
PATM
19.91%
20.32%
19.22%
18.24%
19.60%
21.47%
19.25%
19.23%
EPS
21.84
18.58
17.55%
20.76
17.27
20.21%
20.37
19.61
3.88%
17.97
16.04
12.03%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
5,201.63
4,648.10
4,208.71
3,742.64
3,340.99
2,889.69
2,587.87
2,055.37
2,125.76
1,983.26
1,733.98
Net Sales Growth
14.78%
10.44%
12.45%
12.02%
15.62%
11.66%
25.91%
-3.31%
7.19%
14.38%
 
Cost Of Goods Sold
1,162.37
892.19
880.13
869.31
677.73
514.99
537.75
295.72
317.35
322.58
317.33
Gross Profit
4,039.26
3,755.91
3,328.58
2,873.33
2,663.26
2,374.70
2,050.12
1,759.65
1,808.41
1,660.68
1,416.65
GP Margin
77.65%
80.81%
79.09%
76.77%
79.71%
82.18%
79.22%
85.61%
85.07%
83.73%
81.70%
Total Expenditure
3,843.06
3,388.60
3,036.77
2,959.39
2,411.70
1,891.13
1,904.55
1,488.94
1,467.37
1,296.38
1,146.92
Power & Fuel Cost
-
70.34
66.57
65.71
54.38
43.70
38.88
32.65
27.42
18.70
15.49
% Of Sales
-
1.51%
1.58%
1.76%
1.63%
1.51%
1.50%
1.59%
1.29%
0.94%
0.89%
Employee Cost
-
1,089.69
900.34
785.14
645.78
548.25
485.59
430.71
376.47
295.42
256.64
% Of Sales
-
23.44%
21.39%
20.98%
19.33%
18.97%
18.76%
20.96%
17.71%
14.90%
14.80%
Manufacturing Exp.
-
322.39
303.29
320.81
275.42
226.20
204.81
174.78
215.80
192.70
174.40
% Of Sales
-
6.94%
7.21%
8.57%
8.24%
7.83%
7.91%
8.50%
10.15%
9.72%
10.06%
General & Admin Exp.
-
435.55
382.26
365.86
300.83
131.64
159.49
149.90
131.92
92.02
66.24
% Of Sales
-
9.37%
9.08%
9.78%
9.00%
4.56%
6.16%
7.29%
6.21%
4.64%
3.82%
Selling & Distn. Exp.
-
482.41
417.54
463.94
400.29
374.73
413.70
320.99
306.30
270.92
245.92
% Of Sales
-
10.38%
9.92%
12.40%
11.98%
12.97%
15.99%
15.62%
14.41%
13.66%
14.18%
Miscellaneous Exp.
-
96.03
86.64
88.62
57.27
51.62
64.33
84.19
92.11
104.04
245.92
% Of Sales
-
2.07%
2.06%
2.37%
1.71%
1.79%
2.49%
4.10%
4.33%
5.25%
4.09%
EBITDA
1,358.57
1,259.50
1,171.94
783.25
929.29
998.56
683.32
566.43
658.39
686.88
587.06
EBITDA Margin
26.12%
27.10%
27.85%
20.93%
27.81%
34.56%
26.40%
27.56%
30.97%
34.63%
33.86%
Other Income
128.75
94.50
84.60
98.64
115.68
25.98
92.19
21.08
24.16
23.86
21.15
Interest
19.82
20.73
7.21
5.84
10.20
8.27
11.91
1.16
0.41
1.36
4.89
Depreciation
167.55
144.11
135.40
130.80
125.29
116.09
95.71
72.08
59.59
61.21
44.43
PBT
1,299.95
1,189.16
1,113.93
745.25
909.48
900.18
667.89
514.27
622.55
648.17
558.89
Tax
285.39
268.77
297.76
157.27
196.80
246.31
196.27
127.30
153.91
141.34
143.28
Tax Rate
21.95%
22.60%
26.73%
21.10%
21.64%
27.36%
29.56%
24.75%
24.72%
21.81%
25.64%
PAT
1,014.56
920.39
816.17
587.98
712.68
653.87
467.70
386.97
468.64
506.83
415.61
PAT before Minority Interest
1,014.56
920.39
816.17
587.98
712.68
653.87
467.70
386.97
468.64
506.83
415.61
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
19.50%
19.80%
19.39%
15.71%
21.33%
22.63%
18.07%
18.83%
22.05%
25.56%
23.97%
PAT Growth
13.00%
12.77%
38.81%
-17.50%
8.99%
39.81%
20.86%
-17.43%
-7.54%
21.95%
 
EPS
81.23
73.69
65.35
47.08
57.06
52.35
37.45
30.98
37.52
40.58
33.28

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
3,790.29
3,567.36
3,387.99
3,264.34
2,995.63
2,598.87
2,245.21
2,041.37
1,567.69
1,190.86
Share Capital
25.07
25.27
25.27
17.17
17.39
17.54
17.54
17.69
17.69
17.69
Total Reserves
3,760.04
3,536.44
3,362.38
3,246.87
2,977.70
2,580.86
2,226.57
2,022.05
1,550.00
1,173.17
Non-Current Liabilities
42.13
40.82
177.38
285.02
274.55
227.61
162.23
38.56
8.90
28.63
Secured Loans
0.00
0.00
1.25
1.64
1.60
0.74
0.66
1.01
1.04
5.79
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
9.08
Long Term Provisions
80.27
39.54
146.55
216.04
208.12
155.01
134.15
13.16
4.88
2.59
Current Liabilities
996.10
895.25
1,139.28
647.39
838.82
745.53
498.35
346.05
246.66
259.89
Trade Payables
454.20
463.20
422.77
327.17
373.86
362.34
225.18
249.63
178.18
145.57
Other Current Liabilities
478.02
369.52
669.42
301.47
214.14
180.12
111.45
63.95
46.33
56.72
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
42.85
33.34
0.00
0.00
46.25
Short Term Provisions
63.88
62.53
47.09
18.75
250.82
160.22
128.38
32.47
22.15
11.35
Total Liabilities
4,828.52
4,503.43
4,704.65
4,196.75
4,109.00
3,572.01
2,905.79
2,425.98
1,823.25
1,479.38
Net Block
1,762.02
1,479.19
1,496.44
1,503.58
1,541.11
1,472.14
1,168.35
1,052.66
589.17
450.74
Gross Block
2,801.05
2,389.41
2,282.82
2,206.86
2,140.80
1,976.15
1,578.96
1,417.23
894.94
715.73
Accumulated Depreciation
1,039.03
910.22
786.38
703.28
599.69
504.01
410.61
364.57
305.77
264.99
Non Current Assets
1,985.49
1,773.02
1,870.65
1,932.29
1,891.22
1,790.94
1,605.27
1,202.36
972.65
716.11
Capital Work in Progress
176.27
256.45
209.47
152.86
108.19
131.86
261.61
61.33
254.22
198.91
Non Current Investment
25.24
18.58
25.10
25.10
0.00
12.28
22.87
7.58
0.00
0.00
Long Term Loans & Adv.
18.25
14.43
134.79
236.46
230.74
164.20
148.36
76.79
41.88
21.29
Other Non Current Assets
3.71
4.37
4.85
5.88
11.18
10.46
4.08
4.00
2.34
4.28
Current Assets
2,829.70
2,722.07
2,825.18
2,264.46
2,217.78
1,781.07
1,300.52
1,223.62
850.60
763.27
Current Investments
438.71
330.05
510.27
121.86
175.67
67.14
64.74
182.38
181.56
76.78
Inventories
903.85
828.36
815.63
791.07
766.47
495.68
435.71
350.63
211.02
204.58
Sundry Debtors
1,182.74
1,246.84
1,056.90
1,019.81
738.43
775.30
459.48
459.79
323.15
372.35
Cash & Bank
176.24
130.77
330.90
211.79
209.61
205.25
100.51
93.09
69.95
43.37
Other Current Assets
128.16
53.76
22.09
34.79
327.60
237.70
240.08
137.73
64.92
66.19
Short Term Loans & Adv.
89.36
132.29
89.39
85.14
223.45
168.68
143.45
23.11
56.29
59.39
Net Current Assets
1,833.60
1,826.82
1,685.90
1,617.07
1,378.96
1,035.54
802.17
877.57
603.94
503.38
Total Assets
4,815.19
4,495.09
4,695.83
4,196.75
4,109.00
3,572.01
2,905.79
2,425.98
1,823.25
1,479.38

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
1,157.23
785.07
792.11
561.71
576.31
456.77
374.51
281.12
609.29
326.14
PBT
1,189.16
1,113.93
745.25
909.48
900.18
663.97
514.27
622.56
648.17
558.90
Adjustment
112.11
83.03
131.30
91.75
115.27
70.79
61.93
52.48
86.33
53.07
Changes in Working Capital
178.93
-99.76
66.85
-200.39
-208.75
-123.16
-83.46
-254.32
25.88
-124.34
Cash after chg. in Working capital
1,480.20
1,097.20
943.40
800.84
806.70
611.60
492.74
420.72
760.38
487.63
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-322.97
-312.13
-151.29
-239.13
-230.39
-154.83
-118.23
-139.60
-151.09
-161.49
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-376.52
65.39
-559.60
-74.10
-282.38
-224.40
-222.78
-256.11
-383.12
-209.07
Net Fixed Assets
-324.07
-156.03
-150.65
-110.38
-137.02
-255.91
-361.08
-327.21
-235.38
-197.00
Net Investments
-114.70
186.12
-388.41
-7.97
-71.11
7.11
107.76
-1.82
-104.79
-17.41
Others
62.25
35.30
-20.54
44.25
-74.25
24.40
30.54
72.92
-42.95
5.34
Cash from Financing Activity
-733.41
-1,051.06
-108.20
-459.71
-318.29
-128.63
-147.46
-0.20
-201.77
-117.32
Net Cash Inflow / Outflow
47.30
-200.60
124.31
27.90
-24.36
103.74
4.27
24.81
24.40
-0.25
Opening Cash & Equivalents
129.49
329.83
206.36
177.51
202.35
95.16
90.64
65.83
41.42
41.67
Closing Cash & Equivalent
176.79
129.23
330.67
205.41
177.99
198.90
94.91
90.64
65.82
41.42

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
303.04
282.89
269.07
254.80
230.83
297.80
257.19
231.78
178.14
135.31
ROA
19.72%
17.73%
13.21%
17.16%
17.03%
14.44%
14.52%
22.06%
30.69%
31.66%
ROE
25.06%
23.49%
17.68%
22.77%
23.38%
19.32%
18.07%
25.98%
36.75%
40.92%
ROCE
32.87%
32.22%
22.57%
29.37%
32.20%
27.44%
23.84%
34.49%
45.74%
51.61%
Fixed Asset Turnover
3.43
3.42
3.19
1.56
1.43
1.46
1.37
1.84
2.49
2.76
Receivable days
49.80
52.69
52.87
94.50
93.66
87.08
81.62
67.06
63.41
65.84
Inventory Days
35.51
37.60
40.91
83.71
78.09
65.68
69.82
48.10
37.89
37.93
Payable days
187.66
183.71
157.44
188.77
260.89
59.55
63.24
57.26
50.30
41.91
Cash Conversion Cycle
-102.34
-93.41
-63.66
-10.56
-89.14
93.21
88.21
57.90
51.01
61.86
Total Debt/Equity
0.00
0.00
0.00
0.00
0.00
0.02
0.02
0.00
0.00
0.07
Interest Cover
58.36
155.50
128.61
90.16
109.85
56.75
444.34
1519.41
477.60
115.29

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Ajanta Pharma - Quarterly Results
    31st Jan 2026, 00:00 AM

    Read More
  • Ajanta Pharma incorporates wholly owned subsidiary in Ireland
    13th Jan 2026, 16:26 PM

    The wholly owned subsidiary has been incorporated in Ireland for the purpose of carrying on the business of pharmaceutical products

    Read More
  • Ajanta Pharma enters into in-licensing agreement with Biocon
    24th Dec 2025, 10:12 AM

    Semaglutide, the GLP-1 receptor agonist, is to improve glycaemic control in adults

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.